Lista de obras - Siqing Fu - Dominio Público Uruguay

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

artículo científico publicado en 2015

A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver

artículo científico publicado en 2010

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.

artículo científico publicado en 2015

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

scientific article published on 20 June 2018

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.

artículo científico publicado en 2012

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

artículo científico publicado en 2014

An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.

artículo científico publicado en 2015

Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3

artículo científico publicado en 2012

Body composition and survival in the early clinical trials setting.

artículo científico publicado en 2013

Cancer-Related Internet Use and its Association with Patient Decision Making and Trust in Physicians among Patients in an Early Drug Development Clinic (Preprint)

article

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

artículo científico publicado en 2017

Clinical application of oxaliplatin in epithelial ovarian cancer.

artículo científico publicado en 2006

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

artículo científico publicado en 2018

Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells

artículo científico publicado en 2018

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials

scientific article published on 20 February 2018

Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.

artículo científico publicado en 2008

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

artículo científico publicado en 2015

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver

artículo científico publicado en 2012

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

artículo científico publicado en 2014

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

artículo científico publicado en 2012

Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells

artículo científico publicado en 2013

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

artículo científico publicado en 2017

Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases

scientific article published on 01 April 2016

Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy

artículo científico publicado en 2012

Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases

artículo científico publicado en 2010

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2017

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

artículo científico publicado en 2014

Genetic therapy of human neoplastic disease.

artículo científico publicado en 1993

Immunobiology of gestational trophoblastic diseases.

artículo científico publicado en 2006

Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation

artículo científico publicado en 2002

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

artículo científico publicado en 2017

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

artículo científico publicado en 2013

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

artículo científico publicado en 2012

Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis

artículo científico publicado en 2012

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

artículo científico publicado en 2016

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

artículo científico publicado en 2012

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

artículo científico publicado en 2017

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

artículo científico publicado en 2013

Micrometastases detected by cytokeratin 19 expression in sentinel lymph nodes of patients with early-stage cervical cancer.

artículo científico publicado en 2006

Mobilization of hematopoietic stem cells.

artículo científico publicado en 2000

Molecular approaches to the diagnosis and treatment of cancer.

artículo científico publicado en 1993

Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction

artículo científico

Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer

artículo científico publicado en 2009

Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program

artículo científico publicado en 2011

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.

artículo científico publicado en 2017

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

artículo científico publicado en 2012

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction

artículo científico publicado en 2007

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

artículo científico publicado en 2012

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

artículo científico publicado en 2016

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

artículo científico publicado en 2021

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

artículo científico publicado en 2010

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

artículo científico publicado en 2014

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

artículo científico publicado en 2017

Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement

artículo científico publicado en 2010

Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement

artículo científico publicado en 2010

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer

artículo científico publicado en 2016

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

artículo científico publicado en 2013

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

artículo científico publicado en 2015

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

artículo científico publicado en 2013

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

artículo científico publicado en 2016

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

artículo científico publicado en 2020

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers

scientific article published on 26 April 2018

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.

artículo científico publicado en 2015

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

artículo científico publicado en 2017

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

artículo científico publicado en 2017

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

artículo científico publicado en 2015

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

artículo científico publicado en 2016

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

artículo científico publicado en 2018

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

artículo científico publicado en 2017

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.

artículo científico publicado en 2017

Reply to M. Rouanne et al

scientific article published on 01 February 2013

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

artículo científico publicado en 2015

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

artículo científico publicado en 2012

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

artículo científico publicado en 2012

Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.

artículo científico publicado en 2007

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

artículo científico publicado en 2013

Targeting Aurora kinases in ovarian cancer

artículo científico publicado en 2006

Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy

artículo científico publicado en 2015

The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.

scientific article published on January 2014

Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rhl23) to determine transduction frequency and in vivo selection ⬇️

artículo científico publicado el 1 de agosto de 1995

Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial

artículo científico publicado en 2013

Lista de obras de Siqing Fu

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors

A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.

Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3

Body composition and survival in the early clinical trials setting.

Cancer-Related Internet Use and its Association with Patient Decision Making and Trust in Physicians among Patients in an Early Drug Development Clinic (Preprint)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

Clinical application of oxaliplatin in epithelial ovarian cancer.

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials

Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest.

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs

Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases

Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy

Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

Genetic therapy of human neoplastic disease.

Immunobiology of gestational trophoblastic diseases.

Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

Micrometastases detected by cytokeratin 19 expression in sentinel lymph nodes of patients with early-stage cervical cancer.

Mobilization of hematopoietic stem cells.

Molecular approaches to the diagnosis and treatment of cancer.

Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction

Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer

Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement

Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.

Reply to M. Rouanne et al

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations

Targeting Aurora kinases in ovarian cancer

Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy